Navigation Links
Naurex to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Date:1/9/2014

EVANSTON, Ill., Jan. 9, 2014 /PRNewswire/ -- Naurex Inc. today announced that Norbert G. Riedel, Ph.D., long-term board member and newly-appointed president and chief executive officer of Naurex, will present at the 32nd Annual J.P. Morgan Healthcare Conference at 3 p.m. PST on Tuesday, January 14, 2014 at the Westin St. Francis Hotel in San Francisco. Dr. Riedel will provide an overview of the company and discuss its two clinical-stage rapid-acting antidepressant drug candidates, GLYX-13 and NRX-1074.

About Naurex
Naurex is a clinical-stage biopharmaceutical company developing products to treat diseases of the central nervous system (CNS). The company's lead compound, GLYX-13, has shown promising rapid-acting antidepressant activity with excellent safety and no psychomimetic side effects in a Phase 2a clinical trial. GLYX-13 is currently in a Phase 2b repeat dose study as adjunctive therapy for major depressive disorder. Naurex's 2nd-generation antidepressant, NRX-1074, is in Phase 1 clinical trials. Naurex's proprietary platform is focused on discovering novel compounds that act at the NMDA receptor to modulate neuronal plasticity and hold therapeutic potential for a number of CNS indications. For more information, visit www.naurex.com.

Contacts:
Naurex Inc.
Ashish Khanna
Vice President, Corporate Development
T: 847-871-0377
corporate@naurex.com

Media and Investors
Russo Partners, LLC
Robert Flamm, Ph.D.                             
Matt Middleman, M.D.
T: 212-845-4226                                     
T: 212-845-4272
robert.flamm@russopartnersllc.com 
matt.middleman@russopartnersllc.com 


'/>"/>
SOURCE Naurex Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Naurex Names Dr. Norbert G. Riedel President and Chief Executive Officer
2. Naurex Announces Issuance Of New Patent For Novel Antidepressant GLYX-13
3. Amgen To Present At The 32nd Annual J.P. Morgan Healthcare Conference
4. CID Management Presents "Uncapping the Truth"
5. NW Bio To Present At Biotech Showcase 2014
6. Healthcare Companies Report Conference Presentation Schedule, Stock Price Updates, and Clinical Study Results - Research Report on Medivation, Envision Healthcare, Fonar, Idera Pharma, and Neurocrine
7. Soligenix to Present at the 2014 Biotech Showcase in San Francisco
8. ProteinSimple to Present at the 32nd Annual J.P. Morgan Healthcare Conference
9. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
10. Perrigo Company plc To Host Investor Day And To Present At The 32nd Annual J.P. Morgan Healthcare Conference
11. Heska Corporation to Present at the Sidoti Semi-Annual Micro-Cap Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Henry Schein, Inc. ... health care products and services to office-based dental, animal health ... percent equity investment in Marrodent, one of Poland,s ... approximately $32 million. This transaction was announced on August 30, ... in Poland since 2014, and Marrodent ...
(Date:12/8/2016)... Research and Markets has announced the addition of ... their offering. ... The report provides separate comprehensive analytics for the ... Rest of World. Annual estimates and forecasts are provided ... provided for these markets. Market data and analytics are derived from primary ...
(Date:12/7/2016)... , Dec. 7, 2016 "Lantus (Insulin Glargine) Biosimilar Clinical ... on 37 biosimilar version of Lantus drug in clinical pipeline. Currently 5 ... , Japan , Kenya , ... Germany , China , Slovakia ... 1 & 2 diabetes mellitus. The patent on Lantus expired in 2014. ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... "Today, MHA ... most comprehensive mental health systems reform legislation in more than fifty years. We ... the commitment of our elected officials to improving mental health services and supports ...
(Date:12/7/2016)... ... December 07, 2016 , ... Silhouette Instalift is a simple, ... and tightening the skin of the face to create more youthful features. While ... very little downtime, Silhouette Instalift is a novel, minimally invasive facial procedure that ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... a purchase price of approximately $17.4 million (net of the cash acquired), ... approximately $13.2 million. Headquartered in Barcelona, Spain, Presence is a leading provider ...
(Date:12/7/2016)... Valley, CA (PRWEB) , ... December 07, 2016 , ... ... be used in several ways to restore a more youthful appearance to the face. ... now offer Sculptra, along with a variety of other treatments, to rejuvenate and renew ...
(Date:12/7/2016)... , ... December 07, 2016 , ... They are musicians ... sisters and wives, brothers and fathers, from New England and around the nation. What ... stigma, and are brought together in a beautiful and compelling new photographic exhibit debuting ...
Breaking Medicine News(10 mins):